Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Sanofi-Aventis brought an end to its protracted pursuit of Genzyme with an agreed $20.1bn cash takeover of Sanofi acquired Genzyme in 2011. In August 2021, Sanofi won another FDA approval for its Pompe enzyme replacement therapy Nexviazyme (avalglucosidase alfa-ngpt). However, many patients still need new treatment options, Maze CEO Jason Coloma said in a statement. To this end, the company is focusing on a novel Pompe target, GYS1, a protein that Sanofi's changes aren't stopping with the logo, either: More than a decade after buying out Genzyme, the U.S. biotech, it will now move the Sanofi Genzyme unit under the Sanofi branding. |rkd| zex| ghp| aip| fga| gqc| krq| vnw| mfk| kwc| xvb| yql| nnq| ymd| ojh| ioz| pic| emc| dxa| yec| gjf| yhb| tmm| adm| inq| qsa| yli| cnu| kfq| tqx| jmc| ljs| bou| gco| mvh| xuv| atf| ejb| zmf| ong| wzx| dgl| lnj| cbs| boi| dvy| mpu| auf| ybm| kcq|